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Abstract
Nectin-2 is a transmembrane glycoprotein which is involved in the process of Ca2+-indepen-
dent cell-cell adhesion. In our previous study, we have demonstrated that Nectin-2 is over-
expressed in breast and ovarian cancer tissues by using gene expression analysis and
immunohistochemistry. Furthermore, we discovered multiple anti-Nectin-2 fully human
monoclonal antibodies which inhibited tumor growth in in vivo subcutaneous xenograft mod-
els with antibody-dependent cellular cytotoxicity (ADCC) as the principal mechanism of
action. In this report, we assessed the toxicity of Y-443, a fully human IgG1/kappa anti-Nec-
tin-2 monoclonal antibody exhibiting strong in vitro ADCC and in vivo anti-tumor activity in
cynomolgus monkeys (Macaca fascicularis (Cynos)). Unexpectedly, upon administration,
Y-443 induced strong thrombocytopenia through Nectin-2 expressed on Cyno platelets, pre-
sumably followed by phagocytosis in the mononuclear phagocytic system. To mitigate the
adverse safety profile, we mutated the Fc region of Y-443 to reduce the Fc binding activity to
Fcγ receptor I, which is the primary receptor for phagocytosis on macrophages. Moreover,
we further engineered the Fc through defucosylation to maintain ADCC activity. The resul-
tant Fc engineered antibody, termed Y-634, demonstrated diminished thrombocytopenia in
Cyno toxicological studies and maintained anti-tumor activity in a mouse xenograft model.
These findings suggest that Y-634 may have a therapeutic potential for the treatment of
Nectin-2 positive cancers, and moreover, Fc engineering is a potential mitigation strategy to
ameliorate safety liabilities in antibody induced thrombocytopenia while maintaining anti-
body potency.
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Introduction
Nectin-2, a single-pass type I transmembrane glycoprotein with an extracellular region con-
sisting of three immunoglobulin (Ig) -like domains, is a plasma membrane component of
adherens junctions that mediates Ca2+-independent cell-cell adhesion [1]. Previous studies
reported that the second Ig-like domain is important for the formation of Nectin-2-Nectin-2
homo-cis-dimers [1–8]. The Nectin-2 homo-cis-dimer is able to interact with other Nectin-2
homo-cis-dimer or Nectin-3 homo-cis-dimer expressed on other cells to form homo-trans-
dimers or hetero-trans-dimers, respectively, via the first Ig-like domain in Nectin-2 or Nectin-
3 [1–8]. Those homo- and hetero-trans-dimers then induce other cell-cell adhesion event via
other cell adhesion molecules such as E-cadherin and claudin, to form tight junction [9–12].
Nectin-2 also plays a role as organizer of Sertoli cell-spermatid junctions and synapse forma-
tion in testes and neurons, respectively [13–15]. Furthermore, in addition of cell adhesion
functions, Nectin-2 mediates both entry and spreading of infection from various viruses [16]
and has also been reported that DNAM-1 (CD226) and TIGIT interact Nectin-2 to activate
immune cells [17–20].
In a previous study, we reported that Nectin-2 is over-expressed in breast and ovarian can-
cer and is involved in cancer proliferation [21]. We generated numerous Nectin-2-specific
fully human monoclonal antibodies (mAbs) and demonstrated the anti-tumor effect of the
selected mAb clone, Y-443 (human IgG1/kappa), on breast cancer and ovarian cancer cells
[21]. We also performed in vitro and in vivo studies of Y-443 and Y-443 IgG4 (where the con-
stant region is substituted to human IgG4 isotype) and found that the main mechanism of
action appeared to be antibody-dependent cellular cytotoxicity (ADCC) [21].
The toxicological studies have been conducted in cynomolgus monkeys (Macaca fascicu-
laris (Cynos)) since Y-443 did not cross-react to mouse Nectin-2, but cross-reacted Cyno Nec-
tin-2 with affinity nearly identical to human Nectin-2. While the anti-tumor effect was
promising, the anti-Nectin-2 mAb exhibited unexpected “idiopathic thrombocytopenic pur-
pura (ITP)-like” thrombocytopenia in Cynos. ITP is an immune-mediated bleeding disease
chiefly caused by autoantibodies directed against membrane-bound targets including GPIIb/
IIIa and GPIb-IX on platelets [22–24], resulting in phagocytosis in the mononuclear phago-
cytic system (MPS). Conversely, it has been reported that other platelet antigens can cause
thrombocytopenia via alternative mechanism of actions [25, 26]. In addition to autoantibodies,
it has also been reported that therapeutic antibodies such as anti-TNFα (infliximab), anti-
CD11a (efalizumab), and anti-CD20 (rituximab) antibodies occasionally trigger platelet-spe-
cific autoantibodies and induce thrombocytopenia; however the mechanism of action
remained unclear [27]. Previous reports have shown that the clearance of platelets coated with
IgG autoantibodies is accelerated by phagocytosis through Fcγ receptors (FcγRs) expressed on
tissue macrophages in the reticuloendothelial system, particularly in the spleen [22, 23, 28].
Wallace et al. suggested that FcγRI is the most relevant to phagocytosis of antibody-bound
platelets by macrophages [29], and intravenous infusion of gammaglobulin (IVIg) and Fcγ
fragments has been used clinically for the treatment of such ITP to prevent the phagocytic
events [30, 31].
Therapeutic antibodies are predominantly comprised of human IgG1 and can elicit
immune effector functions via the engagement of both humoral and cell-mediated immunity
through interaction with the Fc portion of the antibody. It has been reported that Leu234-
Gly237 of human IgG1, particularly Leu
235 is a critical amino acid for mediating the Fc-FcγRI
interaction [32–37]. In this paper, we report that the anti-Nectin-2 antibody Y-443 induces
strong thrombocytopenia in Cynos. We further present the ability of Fc engineering, including
Leu235-substitution and defucosylation of Y-443, to ameliorate thrombocytopenia through
Improvement of thrombocytopenia by Fc mutated antibody
PLOS ONE | https://doi.org/10.1371/journal.pone.0196422 May 3, 2018 2 / 17
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have read the
journal’s policy and have the following conflicts: All
authors are/were employees of Takeda
Pharmaceutical Company Limited and were paid as
such. There are no patents, products in
development, or marketed products to declare.
This does not alter our adherence to PLOS ONE
policies in sharing data and materials.
decreased binding to FcγRI while presenting ADCC that is essential for its pharmacological
activity.
Materials and methods
Cells
MDA-MB-231 cells were purchased from the American Type Culture Collection. MDA-MB-
231 cells were grown in Leibovitz’s L-15 medium containing 10% fetal bovine serum in a
humidified incubator at 37˚C.
Preparation of recombinant proteins
Recombinant extracellular domains (ED) of human or Cyno Nectin-2 fused with FLAG (Nec-
tin-2-ED-FLAG) or human Fc (Nectin-2-ED-Fc) at its C-terminus were prepared as described
previously [21]. Recombinant human FcγRI and FcγRIIa were purchased from R&D systems.
Recombinant human FcγRIIb and FcγRIIIa (158F) were prepared in-house. Briefly, a eukary-
otic expression vector pcDNA3.1 in which a cDNA encoding a sequence of extracellular
domain of FcγR with a 6 histidine-tag at its C-terminus was inserted was constructed, and it
was transiently expressed in FreeStyle 293-F cells by FreeStyleTM 293 Expression System (Invi-
trogen). The recombinant proteins were purified from the culture supernatant by Ni-NTA
Agarose affinity chromatography.
Production and Fc modification of anti-Nectin-2 mAbs
Anti-Nectin-2 fully human mAb, Y-443, was generated by immunizing transchromosomic
fully human antibody producing mice carrying the complete locus for the human immuno-
globulin heavy chain gene and a transgene for the human immunoglobulin kappa light chain
(Kyowa Hakko Kirin Co., Ltd.) with recombinant Nectin-2 protein as described previously
[21]. The cDNAs encoding the variable regions of heavy chain and light chain of the antibody
were isolated from the hybridoma, and were inserted into the GS expression vector pEE6.4
(Lonza Biologics) with human IgG1 constant region and pEE12.4 (Lonza Biologics) with
human kappa constant region, respectively. The two vectors were combined to obtain a
double-gene vector carrying the heavy and light chain according to the manufacturer’s guide-
lines. The expression vector was transfected into CHOK1SV cells, and a stable transfectant
was obtained according to manufacturer’s standard protocols. The stable transfectant was
expanded in CD CHO medium (Invitrogen) containing 25 mM methionine sulfoximine, and
the recombinant Y-443 antibody was purified from the culture supernatant by recombinant
protein A chromatography (MabSelect SuRe, GE Healthcare), followed by ion-exchange chro-
matography using Capto Q and Capto S columns (GE Healthcare). The purified Y-443 was
concentrated and buffer-exchanged in Dulbecco’s phosphate buffered saline. Endotoxin
removal was performed using ActiClean Etox resin (Sterogene Bioseparations) according to
manufactures guidelines.
To generate Fc mutants, a single amino acid mutation to aspartic acid (Asp, D) or tyrosine
(Tyr, Y) was introduced at leucine (Leu, L) position 235 (Kabat numbering) in the heavy chain
gene of Y-443 using QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) with
corresponding primers and the double gene vector encoding Y-443 as a template. The Fc
mutant vectors were transiently transfected to FreeStyle 293-F cells using the FreeStyleTM 293
Expression System. The recombinant Fc variant antibodies were purified from the culture
supernatant by Protein A chromatography, followed by size-exclusion chromatography and
membrane filtration.
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The recombinant defucosylated Y-443 (L235D) antibody, termed Y-634, was prepared by
transfection of Y-443 (L235D) plasmid into fucosyltransferase knockout CHO cells (POTEL-
LIGENT1 Cells, BioWa, Inc.) and stable transfectants were generated. One of the stable trans-
fectants, #90–4, was further cultured in 90% CD CHO, 10% CD DG44 (Invitrogen) medium,
and the expressed Y-634 was purified from the culture supernatant as described in aforemen-
tioned methods.
Analysis of recombinant anti-Nectin-2 mAbs
The purity of the recombinant antibodies was tested by SDS-PAGE and a size-exclusion chro-
matography using Superdex 200 10/300 GL (GE Healthcare). Endotoxin content was mea-
sured by Endospecy ES-24S Set (Seikagaku Co.). L-fucose content of the antibodies was
determined by the carbohydrate constituent analysis [38].
Binding activity of anti-Nectin-2 mAbs to human and Cyno Nectin-2 or
human FcγRs
Antigen binding affinity of the anti-Nectin-2 mAbs was evaluated by a kinetic measurement
with a BIACORE 2000 using recombinant human and Cyno Nectin-2-ED-Fc proteins, and the
equilibrium dissociation constant (KD) was determined using BIAevaluation software. The bind-
ing of Y-443 and the Fc engineered antibodies against human FcγRs was measured by an ELISA
using immunoplates coated with recombinant human FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa
(158F). Various concentrations of antibodies were applied to the plates, and the bound antibody
was detected by HRP-labeled anti-human IgG (H+L) antibody (Immuno-Biological Labolatories
Co., Ltd). The EC50 was determined by GraphPad Prism (GraphPad Software, Inc.).
Pharmacological studies in mice
The anti-tumor effect of anti-Nectin-2 mAbs was evaluated in a mouse subcutaneous xeno-
graft model. C.B17/Icr-scid/scid Jcl mice (6-week old, female) were purchased from CLEA
Japan. Mice were housed in groups of 5 per plastic cage and were acclimated for at least 7 days
prior to study start. Room temperature was maintained at 24±1˚C with a 12/12 hour light/
dark cycle. Food and water were available ad libitum. A 100 μL volume of MDA-MB-231
breast cancer cells (3 x 106 cells) and Matrigel (Becton Dickinson) was subcutaneously inocu-
lated into the left flank of mice. When the tumor volume reached to around 120–200 mm3, the
mice were randomly grouped. In the first experiment, dose escalating Y-443 (0.1, 0.3, 1, 3 and
10 mg/kg/10 mL) and vehicle (Dulbecco’s phosphate buffered saline (-)) were intravenously
injected to 5 mice in each treatment group once a week for 3 weeks under physical restraint.
Tumor diameter was measured with a calliper twice per week and the approximate tumor vol-
ume was calculated by the equation of 0.5 x length x (width)2 during the treatment period to
monitor tumor growth. In the second experiment, the anti-tumor effect of Y-634 (0.1, 0.3 and
1 mg/kg/10 mL) was compared to that of Y-443 (0.3 mg/kg/10 mL) using the methodology
described in the first experimental group. Statistical analysis was performed by the Williams’
test.
Housing of Cynos
All of Cynos (Macaca fascicularis at 3 years and 2 months to 5 years and 8 months of age, Nafo-
vanny and/or Siconbrec) were individually housed in metal cages set on racks in an animal
room based on the protocol of toxicological study approved by the Committee on the Ethics of
Animal Experiments of Takeda Pharmaceutical Company Limited. Each monkey was fed 150
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g of a pelleted diet (Certified primate diet #5048, PMI Feeds Inc.) once-daily. The Cynos were
allowed free access to tap water.
Toxicological studies in Cynos
Single dose of Y-443 (1, 3, 10 and 50 mg/kg) and vehicle (25 mM sodium acetate, 125 mM NaCl,
pH 5.5) were intravenously injected (2 mL/minute) to 2 male and 2 female monkeys (Nafovanny
and Siconbrec) in each group followed by 2 weeks observation period. Single dose of Y-634
(10 mg/kg) was also intravenously injected to 2 male monkeys (Siconbrec) followed by 2-week
observation period. Y-634 (3 and 10 mg/kg/week) and vehicle (Dulbecco’s phosphate buffered
saline (-)) were intravenously injected for 3 weeks to 2 female monkeys (Nafovanny and Sicon-
brec) in each group followed by 2-week observation period. Clinical signs, body weights, food
consumption, bleeding time, hematology, coagulation test, gross pathology, organ weights, his-
topathology and/or toxicokinetics were examined. Blood samples for hematology were collected
from femoral vein of each animal using a syringe with sodium heparin and were transferred to
tubes containing EDTA-2K under physical restraint. Blood samples for coagulation test were
collected from femoral vein with a syringe containing 0.1 mL of 3.13% sodium citrate and were
centrifuged at 1500×g for 10 minutes to obtain plasma. The values of hematology were deter-
mined or calculated with an automated hematology analyzer (ADVIA120, Siemens Healthcare
Diagnostics K.K.) and the values for coagulation test were determined with an automated blood
coagulation analyzer (CA-1000, Sysmex Corporation). F gross pathology, organ weights and his-
topathology, all of Cynos were anesthetized by intramuscular injection of ketamine hydrochlo-
ride and were euthanized by exsanguinations from the common carotid artery at necropsy.
Systemic organs for histopathology were fixed in 10 volume percent (vol%) neutral buffered for-
malin. The eyes and testes were fixed in 2.5 weight/volume percent glutaraldehyde in 10 vol%
neutral buffered formalin and Bouin’s fluid, respectively, and then preserved in 10 vol% neutral
buffered formalin. Fixed samples were embedded in paraffin, sectioned, stained with hematoxy-
lin and eosin, and examined microscopically. Blood samples for toxicokinetics were collected
from the vein of the extremities by syringes and transferred to tubes containing separating agent
and were centrifuged at about 1500×g for 15 minutes to obtain plasma and stored in ice.
Measurement of Y-443 or Y-634 in Cyno serum
Cyno serum samples were applied to immunoplates coated with recombinant human Nectin-2
protein (R&D systems). The bound antibody was detected by HRP-labeled anti-human IgG
(H+L) antibody (Immuno-Biological Labolatories Co., Ltd). The serum concentration of Y-
443 or Y-634 was calculated from its standard curve.
ADCC assay
Human peripheral blood mononuclear cells (PBMC) purchased from AllCells, LLC and were
cultured in RPMI1640 medium containing 10% fetal bovine serum, 0.1 nM human IL-2 (DIA-
CLONE Research) and 55 μM 2-mercaptoethanol for 24 hours. PBMC were incubated with
Calcein AM-labeled MDA-MB-231 cells at a ratio of 50:1 in the presence of anti-Nectin-2
mAb for 4 hours at 37˚C. After the incubation, total and dead MDA-MB-231 cell numbers
were measured and dead cell ratio was calculated by Acumen Explorer (TTP labtech).
Ethics statement
All of the animal studies were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
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The protocols were approved by the Committee on the Ethics of Animal Experiments of
Takeda Pharmaceutical Company Ltd. (Permit Numbers for Cyno studies: TEACUC-A1-012
and TEACUC-A1-014, Permit Number for mouse studies: TEACUC-E1-031).
Results
Tumor growth inhibition by Y-443 against MDA-MB-231 in a mouse
subcutaneous xenograft model
We have previously reported that Y-443, one of the anti-Nectin-2 fully human mAbs, signifi-
cantly inhibited tumor growth in a MDA-MB-231 mouse subcutaneous xenograft model
with ADCC as the central mechanism of action [21]. Here, we evaluated Y-443 in the same
MDA-MB-231 mouse subcutaneous xenograft model with lower dose to determine its mini-
mum effective dose. As shown in Fig 1, Y-443 significantly demonstrated potent anti-tumor
effect at 0.3 mg/kg, but not at 0.1 mg/kg.
Adverse effects of Y-443 in Cynos
As described above, Y-443 demonstrated an in vivo anti-cancer effect suggesting the potential
for a therapeutic anti-cancer antibody. Unfortunately, the Y-443 did not cross-react to mouse
Fig 1. Anti-tumor effect of Y-443 in a mouse subcutaneous xenograft model with MDA-MB-231 breast cancer
cells. MDA-MB-231 breast cancer cells were subcutaneously inoculated with Matrigel into a flank of C.B17/Icr-scid/
scid mice. On days 34, 41 and 48 after the cell inoculation, Y-443 at a dose of 0.1, 0.3, 1, 3, 10 mg/kg or vehicle was
intravenously administered (n = 5). The results are the mean ± S.D. of tumor volume. : p< 0.001 versus the tumor
volume treated with vehicle by one-tailed Williams’ test.
https://doi.org/10.1371/journal.pone.0196422.g001
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Nectin-2-ED-Fc; however, Y-443 cross-reacts to Cyno Nectin-2-ED-Fc with a nearly identical
affinity to human Nectin-2-ED-Fc (KD = 5.8 nM vs. 4.9 nM, determined by kinetic analysis
with Biacore). Therefore, toxicological studies were carried out in Cynos. Single intravenous
bolus injection of Y-443 at 10 mg/kg or 50 mg/kg (2 males and 2 females in each group) did
not cause death or treatment-related abnormalities as measured by clinical signs including
body weights and food consumption for 2 weeks over the observation period (data not
shown). However, in the hematological examination, a decrease in platelet count was observed
on days 1 and 7 in nearly all animals dosed at 10 mg/kg. Recovery of the platelet counts was
observed on day 14 in all monkeys with the exception of one male monkey (Table 1 and Fig 2).
At the higher 50 mg/kg dosage, the thrombocytopenia continued for 2 weeks post dosing. The
platelet count decreased to less than 10 x 104/μL in almost all animals dosed at 10 and 50 mg/
kg ranging from 2 to 42% of pre-treatment values. Decreases in erythrocyte count, hematocrit
value and hemoglobin concentration were also observed on days 7 and 14 in one male and all
females dosed with 50 mg/kg Y-443. Additionally, the reticulocyte count was found to be
increased on days 7 and 14 in most animals dosed with 10 and 50 mg/kg (Table 1), but no
changes in leukocytes numbers were observed (data not shown). On day 15, prolongation of
bleeding time was observed in 1 male dosed of 10 mg/kg and the both males and one female
dosed of 50 mg/kg (Table 2). These changes were considered to be secondary events to throm-
bocytopenia. Conversely, no treatment-related abnormality was observed in coagulation tests,
including prothrombin time (PT), activated partial thromboplastin time (APTT) and plasma
fibrinogen in any of the monkeys (Table 2).
All Cynos were sacrificed 2 weeks post dosing and subjected to necropsy and histopatholog-
ical examination. Hemorrhage was observed in several organs (liver, heart, lung, stomach, tes-
tis, pancreas, lymph nodes, thymus, thyroids, adipose tissue in abdominal cavity and skeletal
muscle) for all of the Cynos dosed of 50 mg/kg. Increased spleen weight was observed in 1
male and 1 female dosed of 10 mg/kg and all the Cynos dosed of 50 mg/kg (Table 2). There
were no perceived gender-differences in the aforementioned adverse events. All the symptoms
observed in Y-443-treated Cynos, including thrombocytopenia, bleeding tendency, hemor-
rhage in various organs and splenomegaly, were similar to typical symptom of ITP.
In order to investigate the dose-dependency of the thrombocytopenia, we included two
additional experimental groups, each consisting of two male monkeys treated with bolus injec-
tions of either 1 or 3 mg/kg Y-443. Marked decreases in platelet count were reproduced on day
1 in both administration groups (Fig 2). The platelet count recovered earlier in 1 mg/kg group
compared to the higher dose groups, although, dose-dependency between 3 and 10 mg/kg
groups was insignificant. In toxicokinetics studies, Cynos administered with lower doses of Y-
443, especially in the 1 and 3 mg/kg groups, showed accelerated serum clearance of the anti-
body (Fig 3). Collectively, the results suggest the severity of thrombocytopenia is dependent on
the serum concentration of Y-443.
Fc engineering to mitigate thrombocytopenia
Multiple studies revealed that ITP is triggered by binding of autoantibodies against self-anti-
gens on platelets, and the interaction of the IgG Fc with FcγRI on macrophages drives phago-
cytosis in the spleen [22–24, 31]. As such, we speculated the possibility of mitigating the Y-
443-induced thrombocytopenia through modulating the interaction between the Fc region of
antibody and FcγRI. Fortunately, multiple previous studies revealed that mutations of Leu235
(Kabat numbering) was capable of weakening the Fc-FcγRI interaction [32–37]. Hence, we
generated several Fc mutants of Y-443 and evaluated their binding to recombinant human
FcγRs in an ELISA based assay. Furthermore, we also measured the equilibrium dissociation
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Table 1. Hematology of Y-443-treated Cynos.
Tested Animal Day Erythrocytes Hematocrit Hemoglobin Platelets Reticulocytes
article number (x104/μL) (%) (g/dL) (x104/μL) (x104/μL)
Control 1M001 -4 653 41.3 13.1 45.2 2.6
(male) 1 601 38.0 12.0 39.8 3.0
7 599 38.4 12.1 40.4 5.4
14 584 37.6 11.7 36.2 4.7
1M002 -4 636 40.5 11.7 47.5 1.9
(male) 1 613 38.7 11.3 54.2 1.8
7 638 40.1 12.2 56.5 4.5
14 602 37.5 11.4 61.3 4.2
1F001 -4 587 40.8 12.3 64.0 2.3
(female) 1 522 36.3 11.0 61.4 2.1
7 534 37.5 11.4 69.7 8.5
14 541 38.2 11.6 60.9 7.0
1F002 -4 480 37.7 12.2 37.7 6.2
(female) 1 476 37.1 12.2 36.1 5.2
7 489 38.0 12.7 38.0 6.4
14 492 37.8 12.7 39.6 6.4
Y-443 2M001 -4 563 38.3 12.2 40.3 10.1
(male) 1 533 36.2 11.2 3.0 11.2
10 7 514 34.0 11.2 5.6 23.1
mg/kg 14 548 36.5 11.4 36.3 16.4
2M002 -4 587 42.2 14.0 44.1 8.8
(male) 1 553 38.9 13.3 19.4 8.8
7 527 36.1 12.2 7.4 28.5
14 549 36.3 12.6 9.0 30.2
2F001 -4 637 41.2 13.1 40.4 1.9
(female) 1 581 37.2 11.5 5.5 7.0
7 566 34.5 11.3 6.5 18.7
14 569 35.3 11.4 40.2 15.4
2F002 -4 474 38.3 12.5 49.5 5.7
(female) 1 478 39.0 12.5 38.7 11.0
7 475 38.4 12.7 20.9 17.1
14 482 38.8 12.7 45.0 15.4
Y-443 3M001 -4 663 41.6 13.4 33.5 4.0
(male) 1 648 39.8 12.9 1.4 5.2
50 7 599 36.1 12.2 2.4 18.6
mg/kg 14 633 38.4 12.5 4.1 13.9
3M002 -4 619 40.9 12.7 35.0 2.5
(male) 1 603 39.5 12.1 0.7 3.0
7 496 32.2 10.0 1.1 15.4
14 487 32.7 9.9 4.8 24.4
3F001 -4 570 38.5 12.2 37.3 5.7
(female) 1 547 36.8 11.6 1.3 5.5
7 424 29.5 9.3 3.7 57.7
14 535 37.5 11.5 9.7 14.4
3F002 -4 683 41.3 11.7 53.9 4.1
(female) 1 655 38.4 11.0 1.3 6.6
(Continued)
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constant (KD) against human Nectin-2 by BIACORE to confirm retained target binding activ-
ity of the Fc mutant antibodies. We identified two mutants, Y-443 (L235Y) and Y-443
(L235D), both of which exhibited a significant decrease in binding to FcγRI, but retained anti-
gen binding activity relative to the Y-443 parental antibody (Table 3). The Y-443 (L235Y)
mutant also exhibited moderate decrease in binding to FcγRIIa and FcγRIIb, and 30-fold
reduction in binding to FcγRIIIa (158F). Alternatively, the Y-443 (L235D) mutant displayed a
lesser change in binding to FcγRIIa and FcγRIIb, but only a 5-fold reduction in binding to
FcγRIIIa was observed. Therefore, the Y-443 (L235D) mutant was selected for future studies as
it demonstrated the most desirable features.
In consideration that ADCC is the primary mechanism for anti-tumor effect of Y-443 [21],
the ADCC of the Y-443 mutants was evaluated. As predicted by the decreased affinity to
FcγRIIIa, ADCC of Y-443 (L235D) against MDA-MB-231 breast cancer cells was 10-fold
lower than its parent antibody, Y-443 (Fig 4).
Table 1. (Continued)
Tested Animal Day Erythrocytes Hematocrit Hemoglobin Platelets Reticulocytes
article number (x104/μL) (%) (g/dL) (x104/μL) (x104/μL)
7 423 23.7 7.2 2.0 36.4
14 440 27.4 7.7 5.6 41.8
Day 0: the day of Y-443
https://doi.org/10.1371/journal.pone.0196422.t001
Fig 2. Thrombocytopenia induced by single i.v. administration of Y-443 in Cynos. Platelet count was measured at predose (expressed as day 0)
and on days 1, 4, 7 and 14 after the injection of vehicle or Y-443 (1 mg/kg, 3 mg/kg, 10 mg/kg or 50 mg/kg). Each line indicates platelets count of
individual monkey. Closed circle and closed square are the result of males, and open circle and open square are the ones of females.
https://doi.org/10.1371/journal.pone.0196422.g002
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To rescue the decreased ADCC potency, we prepared a defucosylated variant of the Y-443
(L235D) mutant. Removal of the L-fucose from N-glycan linked to asparagine (Asn) residue at
Kabat position 297 was accomplished by stably expressing a plasmid encoding Y-443 (L235D) anti-
body gene in POTELLIGENT1 Cells. The recombinant defucosylated Y-443 (L235D) antibody,
termed Y-634, was purified from the culture supernatant as described in Materials and Methods.
The L-fucose content of Y-634-derived N-glycan was undetectable compared to those of Y-443
and Y-443 (L235D). The Nectin-2 binding affinity of Y-634 was identical to Y-443 and Y-443
(L235D) (Table 3). Moreover, the ADCC potency of Y-634 was comparable to Y-443 (Fig 4). Thus,
we demonstrate successful development of Y-634, a defucosylated Y-443 (L235D) mutant, with sig-
nificantly reduced binding to FcγRI while maintaining both Nectin-2 binding activity and ADCC.
Toxicological studies of Y-634 in Cynos
To investigate the pharmacovigilance, Y-634 was subjected to toxicological studies in Cynos.
The effect of a single intravenous bolus injection (10 mg/kg) of Y-634 on plasma platelets was
investigated in female monkeys (n = 2). Unfortunately, platelet counts were decreased to 30 x
104 and 41 x 104/μL level on day 1, although, there were no major changes in hematological
values (S1 Table). Nevertheless, the degree of thrombocytopenia was milder than those of Y-
443, and the platelet level was maintained between 29 x 104 and 49 x 104/μL over the two week
observation period. The platelet levels never reached below 10 x 104/μL (or one third of the
normal Cyno’s platelet value), which for comparison, is assumed to be a critical level in human
thrombocytopenia patients for observed prolonged bleeding time in terms of safety (CTCAE
v3.0; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm) (Fig 5 and
S1 Table). In a repeated intravenous administration study in Cynos, dosed at either 3 mg/kg/
week or 10 mg/kg/week (n = 2), platelet counts were maintained above 22 x 104/μL for 4 weeks
after the 1st dosing of Y-634 in the both groups and further reduction by repeated dosing was
not observed. Necropsy or histopathological examination showed no notable changes which
had been observed in the study of Y-443 (data not shown). Ultimately, the severe thrombocy-
topenia induced by Y-443 was markedly reduced through Fc engineering; however, complete
elimination of thrombocytopenia was not observed.
Table 2. Bleeding time, coagulation factors and spleen weight of Y-443-treated Cynos at 2 weeks after dosing.
Tested
article
Dose
(mg/kg)
Sex Animal
number
Bleeding time
day 15
(min)
Coagulation test (day 14) Spleen weight
(% of body weight)PT
(s)
APTT
(s)
Fibrinogen
(mg/dl)
Control Male 1M001 1.5 9.3 19.1 231 0.17
1M002 3.5 8.7 18.8 214 0.23
Female 1F001 1.5 8.7 18.8 239 0.1
1F002 1.5 9.3 25.9 151 0.06
Y-443 10 Male 2M001 2.5 9.3 20.1 221 0.28
2M002 5 9.8 19.3 196 0.29
Female 2F001 1.5 9.4 18.5 253 0.18
2F002 2 8.2 18 174 0.12
Y-443 50 Male 3M001 6 9.9 20.1 157 0.32
3M002 17 9.3 19.2 187 0.35
Female 3F001 3 9 18.5 228 0.25
3F002 12.5 9.2 17.9 200 0.24
PT: Prothrombin time, APTT: Activated partial thromboplastin time
https://doi.org/10.1371/journal.pone.0196422.t002
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Tumor growth inhibition by Y-634 against MDA-MB-231 in a mouse
subcutaneous xenograft model
Y-634 showed similar ADCC activity compared to the parent antibody, Y-443, and demon-
strated partially alleviated thrombocytopenia in Cynos (Fig 4). In the final experiment, we eval-
uated the anti-tumor effect of Y-634 in a mouse subcutaneous xenograft model of MDA-MB-
231 breast cancer cells. Weekly administrations of Y-634 showed significant anti-tumor effect
Fig 3. Serum concentration of Y-443 after a single i.v. administration to Cynos. Cyno sera were corrected 0, 1, 4, 8,
24, 168, 264 and 336 hours after a bolus injection of Y-443 at 1 mg/kg and 3 mg/kg (n = 2), or 0, 1, 4, 8, 24, 168 and 336
hours after the injection of Y-443 at 10 mg/kg and 50 mg/kg (n = 4). Y-443 concentrations in the Cyno sera were
measured by ELISA. The results are the mean ± S.D. of serum antibody concentration. : lower concentration than the
quantification limit (5 ng/mL).
https://doi.org/10.1371/journal.pone.0196422.g003
Table 3. Binding activity of Y-443 and Fc-mutated antibodies to human Nectin-2 and human FcγRs.
KD values against human Nectin-2
Relative binding activity to human FcγRs (%)
FcγRI FcγRIIa FcγRIIb FcγRIIIa (158F)
Y-443 3.2 nM 100 100 100 100
Y-443 (L235Y) 3.3 nM 0.017 26 35 3.4
Y-443 (L235D) 1.5 nM 0.074 64 120 22
Y-634 3.2 nM 0.056 46 81 300
Relative binding activity (%) = EC50 (Y-443) / EC50 (sample) x 100
https://doi.org/10.1371/journal.pone.0196422.t003
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at 0.1 mg/kg and equivalent efficacy to Y-443 at 0.3 mg/kg (Fig 6). Altogether, these
results suggest that Y-634 retains strong anti-tumor effect with significantly reduced
thrombocytopenia.
Discussion
In our previous study, we demonstrated that Nectin-2 is over-expressed in both breast and
ovarian cancers [21]. We subsequently developed an anti-Nectin-2 fully human mAb, Y-443,
which has an in vivo anti-tumor effect on OV-90 and MDA-MB-231 xenograft models through
an ADCC mechanism [21]. Since the Y-443 cross-reacted to Cyno Nectin-2 with equivalent
KD to human Nectin-2 (4.9 nM and 5.8 nM, respectively), we conducted toxicological studies
in Cynos. In a single dose study, intravenous administration of Y-443 (10 and 50 mg/kg)
caused severe thrombocytopenia with prolonged bleeding time in all the animals (Table 1,
Table 2 and Fig 2), despite that clinical signs and other hematological remained normal. Inter-
estingly, the Nectin-2 expression was observed only in liver and testes [21], with negligible
expression on human platelets (data not shown), hence, the adverse events observed in Cynos
Fig 4. ADCC of Y-443 and Fc-mutated antibodies against MDA-MB-231 cells. MDA-MB-231 cells pre-labeled with
Calcein AM were incubated with different concentrations of Y-443 or the Fc mutants, followed by addition of PBMC
effector cells at a ratio of 1:50. The cell mixture was incubated for 4 hours at 37˚C, and Calcein AM intensity in cells
was detected by Acumen eX3 (TTP labtech). The results are the mean ± S.D. of dead cell ratio.
https://doi.org/10.1371/journal.pone.0196422.g004
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were unexpected. Here, Y-443 marginally detected Nectin-2 on Cyno platelets (data not
shown), and furthermore, did not induce aggregation of monkey platelets at 100 μg/mL in in
vitro (data not shown). Moreover, single intravenous administration of Y-443 at 10 and 50
mg/kg gave no meaningful changes in Cyno coagulation test (Table 2). The splenomegaly
observed in those monkeys correlated to the activated phagocytic function of the spleen, which
seemed to cause disposal of platelet-Y-443 complex resulting in thrombocytopenia and faster
serum clearance of the antibody in the lower dose groups. The activated phagocytic function
could conceivably result in the observed anemia of the dosed animals (Table 1). The platelet
count recovered within the two week post-treatment observation period in the lower dosing
groups (1, 3 or 10 mg/kg), but not the 50 mg/kg dosing group (Fig 2). The reversibility of
thrombocytopenia observed in the 1, 3 and 10 mg/kg dosing groups and increased reticulocyte
count (days 7 and 14 in the 10 and 50 mg/kg dosing groups) suggest that the platelet produc-
tion by the bone-marrow was unimpaired by the antibody treatment. The symptoms observed
in Y-443-treated Cynos were similar to symptoms of thrombocytopenia (bleeding tendency,
hemorrhage in organs, and splenomegaly), which were likely to be target mediated toxicity.
ITP is occasionally caused by auto-antibodies against self-antigens on platelets [22–24]. Conse-
quently, the presented data suggests that Y-443 might act like an autoantibody in Cynos by
inducing ITP-like symptoms presumably causing phagocytosis of Y-443-bound platelets by
macrophages in the spleen.
Previous reports suggested that disruption of the interaction of autoantibodies and FcγRI is
useful in preventing phagocytosis of the antibody-coated platelets by macrophages [31]. Addi-
tionally, multiple studies utilizing Fc engineering demonstrated that the mutations of Leu235
were capable of diminishing the Fc-FcγRI interaction [32–37]. We have shown that ADCC
was the main mechanism of tumor regression of anti-Nectin-2 mAb, Y-443, for which binding
of the Fc to FcγRIIIa is essential to maintain ADCC. Therefore, we applied Fc engineering to
reduce the binding affinity of the Y-443 Fc to FcγRI while maintaining its binding to FcγRIIIa.
Mutation of Leu235 resulted in the L235D mutant, Y-443 (L235D), which showed markedly
decreased binding to human FcγRI with only a mild reduction (4.5-times) in binding to
human FcγRIIIa, as compared to the parental Y-443 antibody. However, as predicted, Y-443
Fig 5. Thrombocytopenia induced by single and repeated i.v. administration of Y-634 in Cynos. For the single dose
group (A), platelet count was measured in Cynos treated with 10 mg/kg of Y-634 at predose (expressed as day 0) and
on days 1, 3, 7, 10, 14 and 17. For the weekly repeated intravenous administration (B) of 3 mg/kg (red lines) or 10 mg/
kg (blue lines) of Y-634 dosed on days 0, 7 and 14, platelet count was measured in Cynos at predose (expressed as day
0) and on days 1, 3, 7 (pre 2nd dose), 8, 10, 15, 17, 21 and 28. Each line indicates platelet count of individual monkey.
https://doi.org/10.1371/journal.pone.0196422.g005
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(L235D) showed a 10-fold weaker ADCC against MDA-MB-231 breast cancer cells (Fig 4).
Nevertheless, it has been reported that the lack of L-fucose on N-linked oligosaccharide on
Asn297 of human IgG1 antibodies can enhance their binding affinity to FcγRIIIa and conse-
quently the ADCC. Therefore, we sought to recover the ADCC of Y-443 (L235D) mutant
through defucosylation of the N-glycan on the Asn297 using the POTELLIGENT1 technology
(see Materials and methods) [39, 40]. The defucosylated Y-443 (L235D) variant, Y-634,
showed potent ADCC, comparable to that of the Y-443 antibody while further maintaining
the diminished binding affinity to human FcγRI as observed with the Y-443 (L235D) mutant
(Fig 4 and Table 3). Thus, Y-634 demonstrated diminished thrombocytopenia in the Cynos
both upon single and repeated dose administration, but also maintained the anti-tumor effect
against breast and ovarian cancer cells in mouse xenograft models (Fig 5, Fig 6 and S1 Table).
Although we haven’t evaluated the binding activities of Y-443 mutants to Cyno FcγRs, it has
been reported that human IgG1 bound to Cyno FcγRI and FcγRIIIa with similar binding affin-
ities to human FcγRI and FcγRIII, respectively [41]. In addition, the amino acid sequence of
the human IgG1 binding sites on Cyno FcγRI and FcγRIIIa are nearly identical to those in
human FcγRI and FcγRIIIa, respectively [42, 43]. Therefore, the improved features in Y-634
presumably reflect the binding activities to Cyno FcγRI and FcγRIIIa.
Fig 6. In vivo anti-tumor effect of Y-634 in a mouse subcutaneous xenograft model with MDA-MB-231 cells. Anti-
tumor effect of Y-634 was compared with its parental antibody, Y-443, in a MDA-MB-231 mouse subcutaneous
xenograft model. On days 37, 44 and 51 after MDA-MB-231 cell inoculation, Y-443 at a dose of 0.3 mg/kg, Y-634 at a
dose of 0.1, 0.3 and 1 mg/kg or vehicle was intravenously administered (n = 5). The results are the mean ± S.D. of
tumor volume. : p< 0.001 versus the tumor volume treated with vehicle by one-tailed Williams’ test.
https://doi.org/10.1371/journal.pone.0196422.g006
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In summary, we demonstrated a potential strategy to overcome ITP-like toxicity of thera-
peutic antibodies by combining a single amino acid mutation in Fc region and glyco-engineer-
ing. Our findings may help facilitate the development of antibody therapeutics through a
strategy to reduce observed side effects like thrombocytopenia while maintaining antibody
efficacy.
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